Showing 4771-4780 of 6036 results for "".
- Abbvie and Regenxbio Announce Collaboration to Advance Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-collaboration-to-advance-gene-therapy-for-retinal-diseases/2480427/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in
- iVeena Announces Successful Completion of Pre-IND Meeting with FDAhttps://modernod.com/news/iveena-announces-successful-completion-of-pre-ind-meeting-with-fda/2480426/iVeena Delivery Systems announced completion of a pre-investigational new drug (IND) meeting with the FDA regarding the development plan for a novel pharmacologic treatment of pediatric myopia. IVMED-85 enables physiologic crosslinking in the sclera an
- Alcon to Acquire Ivantis, Maker of the Hydrus Microstent for Surgical Glaucomahttps://modernod.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent. The deal will strenghten Alcon's surgical glaucoma portfolio and allow it to enter the growing MIGS category. Under terms of the deal, Alcon will pay $475 million in upfr
- CooperVision Myopia Control Research Receives Garland W. Clay Awardhttps://modernod.com/news/coopervision-myopia-control-research-receives-garland-w-clay-award/2480405/The American Academy of Optometry has awarded the 2021 Garland W. Clay Award to a team of researchers studying the effectiveness of CooperVision MiSight 1 day contact lenses in slowing the progression of myopia in children (aged 8-12 at the initiation of treatment).
- Alcon Inaugurates Company’s Largest European Eye Health Education and Training Center in Barcelonahttps://modernod.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/Alcon officially opened the new Alcon Experience Center (AEC) in Barcelona, one of Europe's largest eye health education and training facilities, offering eye care professionals the opportunity to learn and gain hands-on experience with the latest innovations in ophthalmology and optometry. T
- Prism Vision Group Acquires Three New Practiceshttps://modernod.com/news/prism-vision-group-acquires-three-new-practices/2480398/PRISM Vision Group announced that it has recently acquired Bethlehem Eye Associates in Bethlehem, Pennsylvania; Schefkind Eye Care with two locations in Alexandria, Virginia; and Carabin Eye Care in New Milford, New Jersey. Terms of the deals were not disclosed.
- CooperVision Presents Presbyopia Research, Introduces MyDay Daily Disposable Multifocal at Academy 2021https://modernod.com/news/coopervision-presents-presbyopia-research-introduces-myday-daily-disposable-multifocal-at-academy-2021/2480390/As part of the American Academy of Optometry 2021 virtual press conference, CooperVision presented results of research into the daily complexity of dealing with presbyopia and how this may affect clinical choices. The work was conducted in support of the launch of CooperVision’s new MyDay&n
- EyeCare Partners Acquires CEI Vision Partnershttps://modernod.com/news/eyecare-partners-acquires-cei-vision-partners/2480383/EyeCare Partners (ECP) announced it entered into an agreement to acquire CEI Vision Partners (CVP), a network of ophthalmology practices in the Midwest and Mid-Atlantic. Financial terms of the transaction were not disclosed. The deal will create a combined group of more t
- EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeuticshttps://modernod.com/news/eyegate-pharmaceuticals-closes-acquisition-of-bayon-therapeutics/2480376/EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’
- Ocular Therapeutix's Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Does Not Meet Primary Endpointhttps://modernod.com/news/ocular-therapeutixs-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease-does-not-meet-primary-endpoint/2480372/Topline results from Ocular Therapeutix's phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED) did not meet its primary endpoint of increased tear production at 12 weeks. The phase 2, US-based, randomized, double-masked,